cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cardiff Oncology Inc
9 own
13 watching
Current Price
$1.73
$0.01
(0.58%)
logo-crdf
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
74.97M
52-Week High
52-Week High
3.7775
52-Week Low
52-Week Low
1.13
Average Volume
Average Volume
0.07M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization74.97M
icon52-Week High3.7775
icon52-Week Low1.13
iconAverage Volume0.07M
iconDividend Yield--
iconP/E Ratio--
What does the Cardiff Oncology Inc do?
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company s TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Read More
How much money does Cardiff Oncology Inc make?
News & Events about Cardiff Oncology Inc.
PR Newswire
2 months ago
Cardiff Oncology to Present at Upcoming Investor Conferences Cardiff Oncology to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO, Nov. 21, 2022 SAN DIEGO, Nov. 21, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1...
PR Newswire
3 months ago
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028 Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028 PR Newswire Palm Beach, Fla., Oct. 12, 2022 FinancialNewsMedia.com News Commentary Palm Beach, Fla., Oct. 12, 2022...
PR Newswire
4 months ago
Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022 Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress...
PR Newswire
5 months ago
Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022 Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022 PR Newswire SAN DIEGO, Aug. 29, 2022 Event to feature...
PR Newswire
6 months ago
Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022 Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022 PR Newswire SAN DIEGO, July 5, 2022 SAN DIEGO, July 5, 2022 /PRNewswire/ --Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...
Frequently Asked Questions
Frequently Asked Questions
What is Cardiff Oncology Inc share price today?
plus_minus_icon
Can Indians buy Cardiff Oncology Inc shares?
plus_minus_icon
How can I buy Cardiff Oncology Inc shares from India?
plus_minus_icon
Can Fractional shares of Cardiff Oncology Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cardiff Oncology Inc stocks?
plus_minus_icon
What is today’s traded volume of Cardiff Oncology Inc?
plus_minus_icon
What is today’s market capitalisation of Cardiff Oncology Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cardiff Oncology Inc?
plus_minus_icon
What percentage is Cardiff Oncology Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cardiff Oncology Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.73
$0.01
(0.58%)
logo-crdf
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SOLID BIOSCIENCES INC
SOLID BIOSCIENCES INC
$7.45
$0.12 (1.57 %)
ORCHARD THERAPEUTICS PLC
ORCHARD THERAPEUTICS PLC
$0.60
$0.02 (3.75 %)
GAMIDA CELL LTD
GAMIDA CELL LTD
$1.55
$0.00 (0.00 %)
AVROBIO INC
AVROBIO INC
$0.86
$-0.02 (-2.34 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
SOLID BIOSCIENCES INC
SOLID BIOSCIENCES INC
$7.45
$0.12 (1.57 %)
ORCHARD THERAPEUTICS PLC
ORCHARD THERAPEUTICS PLC
$0.60
$0.02 (3.75 %)
GAMIDA CELL LTD
GAMIDA CELL LTD
$1.55
$0.00 (0.00 %)
AVROBIO INC
AVROBIO INC
$0.86
$-0.02 (-2.34 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00